WO2003069311A2 - Methodes et compositions destinees a etre utilisees dans le trans-epissage d'arn induit par une epissosome - Google Patents

Methodes et compositions destinees a etre utilisees dans le trans-epissage d'arn induit par une epissosome Download PDF

Info

Publication number
WO2003069311A2
WO2003069311A2 PCT/US2003/004622 US0304622W WO03069311A2 WO 2003069311 A2 WO2003069311 A2 WO 2003069311A2 US 0304622 W US0304622 W US 0304622W WO 03069311 A2 WO03069311 A2 WO 03069311A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecule
mrna
target
trans
Prior art date
Application number
PCT/US2003/004622
Other languages
English (en)
Other versions
WO2003069311A3 (fr
Inventor
Lloyd G. Mitchell
Mariano A. Garcia-Blanco
Madaiah Puttaraju
Original Assignee
Intronn, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/075,028 external-priority patent/US20030153054A1/en
Priority claimed from US10/076,248 external-priority patent/US20020193580A1/en
Application filed by Intronn, Inc. filed Critical Intronn, Inc.
Priority to JP2003568382A priority Critical patent/JP2006505242A/ja
Priority to CA002475802A priority patent/CA2475802A1/fr
Priority to EP03711065A priority patent/EP1539788A2/fr
Priority to AU2003215249A priority patent/AU2003215249B2/en
Publication of WO2003069311A2 publication Critical patent/WO2003069311A2/fr
Publication of WO2003069311A3 publication Critical patent/WO2003069311A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell.
  • the compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation.
  • the synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).
  • the PTMs of the invention are synthetically produced and transferred to a cell so as to result in the production of a novel chimeric RNA which may itself perform a function, such as inhibiting the translation of the RNA, or that encodes a protein that complements a defective or inactive protein in a cell, or encodes a toxin which kills specific cells, or that encodes a marker gene for imaging purposes.
  • the target pre-mRNA is chosen as a target because it is expressed within a specific cell type thus providing a means for targeting expression of the novel chimeric RNA to a selected cell type.
  • the methods of the invention encompass the synthetic production of PTMs, preferably in such a way as to possess enhanced stability against chemical and enzymatic degradation.
  • the methods of the invention further comprise contacting the synthetic PTMs of the invention with a cell expressing a target pre-mRNA under conditions in which the synthetic PTM is taken up by the cell and a portion of the synthetic PTM is trans-spliced to a portion of the target pre-mRNA to form a novel chimeric RNA molecule.
  • the methods and compositions of the invention can be used in cellular gene regulation, gene repair and suicide gene therapy for treatment of proliferative disorders such as cancer or treatment of genetic, autoimmune or infectious diseases.
  • the present invention is based on the observation that direct delivery of in vitro synthesized synthetic PTMs into a target host cell can mediate accurate trans-splicing of target pre-mRNAs to generate novel chimeric RNAs.
  • the present invention bypasses the requirement for efficient delivery of DNA molecules encoding a PTM into a target cell followed by expression of the DNA molecule to form a PTM capable of mediating a trans-splicing reaction.
  • DNA sequences in the chromosome are transcribed into pre-mRNAs which contain coding regions (exons) and generally also contain intervening non- coding regions (introns). Introns are removed from pre-mRNAs in a precise process called splicing (Chow et al, 1977, Cell 12:1-8; and Berget, S.M. et al, 1977, Proc. Natl. Acad. Sci. USA 74:3171-3175).
  • Splicing takes place as a coordinated interaction of several small nuclear ribonucleoprotein particles (snRNP s) ana many protein 'factors that assemble to form an enzymatic complex known as the spliceosome (Moore et al, 1993, in The RNA World, R.F. Gesiland and J.F. Atkins eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Kramer,
  • Pre-mRNA splicing proceeds by a two-step mechanism, hi the first step, the 5' splice site is cleaved, resulting in a "free" 5' exon and a lariat intermediate (Moore, MJ. and P.A. Sharp, 1993, N ⁇ twre 365:364-368). In the second step, the 5' exon is ligated to the 3' exon with release of the intron as the lariat product. These steps are catalyzed in a complex of small nuclear ribonucleoproteins and proteins called the spliceosome.
  • the splicing reaction sites are defined by consensus sequences around the 5' and 3' splice sites.
  • the 3' splice region consists of three separate sequence elements: the branch point or branch site, a polypyrimidine tract and the 3 1 splice consensus sequence (YAG). These elements loosely define a 3' splice region, which may encompass 100 nucleotides of the intron upstream of the 3' splice site.
  • the 3' splice consensus sequence is YAG/G. Between the branch point and the splice site there is usually found a polypyrimidine tract, which is important in mammalian systems for efficient branch point utilization and 3' splice site recognition (Roscigno, R., F. et al, 1993, J. Biol. Chem. 268:11222- 11229).
  • the first YAG trinucleotide downstream from the branch point and polypyrimidine tract is the most commonly used 3' splice site (Smith, C.W. et al, 1989, Nature 342:243-247).
  • trans-splicing Splicing between two independently , , transcribed pre-mRNAs is termed trans-splicing.
  • Trans-splicing was first discovered in trypanosomes (Sutton & Boothroyd, 1986, Cell 47:527; Murphy et al, 1986, Cell 47:517) and subsequently in nematodes (Krause & Hirsh, 1987, Cell 49:753); . .. flatworms (Rajkovic et al, 1990, Proc. Nat'l. Acad. Sci. USA, 87:8879; Davis et al, 1995, J, Biol. Chem.
  • trans-splicing which is nearly identical to that of conventional c/s-splicing, proceeds via two phosphoryl transfer reactions.
  • the first causes the formation of a 2'-5' phosphodiester bond producing a ⁇ ' shaped branched intermediate, equivalent to the lariat intermediate in czs-splicing.
  • the second reaction! proceeds as in conventional c/s-splicing.
  • sequences at the 3' splice site and some of the snR ⁇ Ps which catalyze the trans- splicing reaction closely resemble their counterparts involved in cts-splicing.
  • Trans-splicing may also refer to a different process, where a portion of one pre-mR ⁇ A interacts with a portion of a second pre-mR ⁇ A, enhancing the recombination of splice sites between two conventional pre-mR ⁇ As.
  • This type of trans-splicing was postulated to account for transcripts encoding a human immuno globulin variable region sequence linked to the endogenous constant region in a transgenic mouse (Shimizu et al, 1989, Proc. Nat'l. Acad. Sci. USA 86:8020).
  • trans-splicing o ⁇ c-myb pre-RNA has been demonstrated (Vellard, M. et al., Proc. Nat'l. Acad.
  • RNA transcripts from cloned SN40 trans-spliced to each other were detected in cultured cells and nuclear extracts (Eul et al, 1995, EMBO. J. 14:3226).
  • naturally occurring trans- splicing of mammalian pre-mR ⁇ As is thought to be an exceedingly rare event.
  • a third mechanism involves cutting and joining of the R ⁇ A by the intron itself, by what are termed catalytic R ⁇ A molecules or ribozymes.
  • the cleavage activity of ribozymes has been targeted to specific R ⁇ As by engineering a discrete "hybridization" region into the ribozyme. Upon hybridization to the target R ⁇ A, the catalytic region of the ribozyme cleaves the target. It has been suggested that such ribozyme activity would be useful for the inactivation or cleavage of target R ⁇ A in vivo, such as for the .
  • R ⁇ A antisense R ⁇ A
  • R ⁇ A antisense R ⁇ A
  • small R ⁇ A molecules are designed to hybridize to the target R ⁇ A and by binding to the target R ⁇ A prevent translation of the target R ⁇ A or cause destruction of the R ⁇ A through activation of nucleases.
  • U.S. Patent ⁇ os 6,083,702, 6,013,487 and 6,280,978 describe the use of PTMs to mediate a trans-splicing reaction by contacting a target precursor mR ⁇ A to generate novel chimeric R ⁇ As.
  • the resulting R ⁇ A can encode any gene product including a protein of therapeutic value to the cell or host organism, a toxin, such as Diptheria, which causes killing of the specific cells or a novel protein not normally present in cells.
  • the PTMs can also be engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method and for production of chimeric proteins with peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.
  • nuclear localization signals include small polypeptide sequnces that act as signals for translocation to the cell nucleus (Dingwall and Laskey, 1986, Ann. Rev. Cell Biol. 2:367-390; Dingwall and Laskey 1991, Trends Biochem. Sci., 16:478-481).
  • nucleic acid molecules into host cells include direct injection of naked nucleic acid molecules, microparticle bombardment of nucleic acids (e.g., a gene gun; Bio-Rad,. Dupont), coating nucleic acids with lipids or cell-surface receptors or transfecting agents and encapsulation of nucleic acids in liposomes, microparticles, or microcapsules.
  • Other techniques of gene delivery include calcium phosphate mediated transfection, cationic polymer mediated transfection, lipofection or electroporation. Uncertainties relating to the mechanism of uptake into the cytoplasm and trafficking of DNA to the nucleus where transcription occurs complicate these methods and contribute to low transfection efficiencies.
  • Attenuated viral vectors such as adenovirus (Kozarsky and Wilson, 1993, Current Opinion in Genetics and Development 3:499- 503), retrovirus (U.S. Patent No. 4980286), herpes virus, and adeno-associated virus (AAN)
  • retrovirus U.S. Patent No. 4980286
  • AAN adeno-associated virus
  • retroviral infection can be carcinogenic and stimulate an immune response to viral proteins, causing local inflammation and posing a deterrent to repeat administration.
  • Niral vectors with the exceptions of AAN and lentivirus, are also limited because they can only infect replicating cells.
  • these vectors must be designed with cell-specific, ubiquitous or inducible promoter systems. Accordingly, modulation of gene expression is an additional factor one must consider in the attempt to express a desired gene product in a cell.
  • the drawbacks associated with transfer of DNA into cells which must then be expressed can be overcome by the direct delivery of the RNA or chimeric (RNA/DNA PNA, etc.) molecules to be expressed into the target host cell.
  • the present invention bypasses the requirement for transfer of nucleic acid molecules capable of encoding a PTM into a target cell followed by efficient transcription of said molecules to form PTMs.
  • the present invention is based on the successful delivery of synthetic PTMs into target cells and the demonstration that such synthetic molecules are capable of mediating trans-splicing reactions with target mRNAs to generate novel chimeric RNAs.
  • the present invention relates to compositions and methods of generating novel nucleic acid molecules through spliceosome-mediated targeted trans-splicing. Specifically, the invention provides methods and compositions for the delivery of synthetic PTMs into a target cell.
  • compositions of the invention include synthetic pre-tr ⁇ ns-splicing molecules (hereinafter referred to as "synthetic PTMs”) designed to interact with a natural target pre-mRNA molecule (hereinafter referred to as "pre-mRNA”) and mediate a spliceosomal trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (hereinafter referred to as "chimeric RNA").
  • the synthetic PTMs may comprise modified or substituted nucleotides which are preferred over naturally occurring nucleotides because of desirable properties such as, for example, increased, enhanced cellular uptake, increased targeting to the nucleus of the cell and/or enhanced binding to target cell or target pre-mRNA.
  • carrier or excipients will be chosen based on their ability to stabilize the RNA molecules during in vitro formulation, their ability to increase the stability of the RNA in vivo and/or their ability to increase the efficiency of RNA transfer in vivo, thereby providing a more efficient RNA delivery system.
  • the methods of the invention encompass contacting the synthetic PTMs of the invention with a target cell expressing a natural target pre-mRNA under conditions in which the synthetic PTM is taken up by the cell and a portion of the synthetic PTM is spliced to the natural pre-mRNA to form a novel chimeric RNA.
  • the synthetic PTMs of the invention are genetically engineered so that the novel chimeric RNA resulting from the trans-splicing reaction may itself perform a function such as inhibiting the translation of RNA, or alternatively, the chimeric RNA may encode a protein that complements a defective or inactive protein in the cell, or encodes a toxin which kills the specific cells.
  • the target pre-mRNA is chosen because it is expressed within a specific cell type thereby providing a means for targeting expression of the novel chimeric RNA to a selected cell type.
  • the target cells may include, but are not limited to those infected with viral or other infectious agents, benign or malignant neoplasms, or components of the immune system which are involved in autoimmune disease or tissue rejection.
  • the PTMs of the invention may also be used to correct genetic mutations found to be associated with genetic diseases, hi particular, double-trans-splicing reactions can be used to replace internal exons.
  • the methods and compositions of the invention can be used in gene regulation, gene repair and targeted cell death. Such methods and compositions can be used for the treatment of various diseases including, but not limited to, genetic, infectious or autoimmune diseases and proliferative disorders such as cancer and to regulate gene expression in plants.
  • Figure IA Model of Pre- -Trans-splicing RNA.
  • FIG. 1B Model PTM constructs and targeted trans-splicing strategy.
  • Schematic representation of linear PTMs (PTM+Sp and PTM-Sp).
  • BD binding domain
  • NBD non-binding domain
  • BP branch point
  • PPT pyrimidine tract
  • ss splice site
  • DT-A diphtheria toxin subunit A.
  • Unique restriction sites within the PTMS are indicated by single letters: E; EcoRI; X, Xhol; K, Kpnl; P, Pstl; A, Accl; B, BamHl and H; Hindlll.
  • Figure IC Schematic drawing showing the binding of PTM+Sp via conventional Watson Crick base pairing to the ⁇ HCG6 target pre-mRNA and the proposed czs- and trans-splicing mechanism.
  • FIG. 1 Schematic drawings of constructed pre-mRNA targets (double trans-splicing).
  • Figure 3. Schematic diagrams of double trans-splicing PTM.
  • FIG 4. Diagram and important structural elements of double trans-splicing PTM7.
  • the double splicing PTM7 has both 3' and 5' functional splice sites as well as binding domains.
  • Figure 5. Double trans-splicing ⁇ -gal repair model. Accurate double trans-splicing between the target pre-mRNA and synthetic PTM RNA will result in the production of repaired lacZ mRNA RNA.
  • FIG. 6A-B Successful double trans-splicing of synthetic PTM RNA in transfected 293 T cells.
  • Fig. 6C The accuracy of double trans-splicing of synthetic PTM RNA in 293T cells was verified by sequencing the spliced RNA produ ⁇ ed by RT-rPCR.
  • the present invention provides methods and compositions for delivery of synthetic PTMs into a target cell.
  • the present invention relates to compositions comprising synthetic pre-trans-splicing molecules and a suitable carrier or incipient and the use of such compositions for generating novel nucleic acid molecules within a target cell.
  • the synthetic PTMs are preferably produced with enhanced resistance to enzymatic and/or chemical degradation.
  • the carriers or excipients are designed to stabilize the PTM during in vitro formulation, increase the stability of the PTM in vivo and/or increase the efficiency of PTM transfer in vivo, thereby providing a more efficient PTM delivery system.
  • the synthetic PTMs of the invention comprise one or more target binding domains that are designed to specifically bind to pre-mRNA, a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor site and/or a 5' splice donor site; and one or more spacer regions that separate the RNA splice site from the target binding domain.
  • the synthetic PTMs of the invention can be engineered to contain any additional nucleotide sequences such as those encoding a translatable protein product.
  • the methods of the invention encompass contacting the synthetic PTMs of the invention with a target cell expressing a natural pre-mRNA under conditions in which a portion of the synthetic PTM is trans-spliced to a portion of the natural pre-mRNA to form a novel chimeric RNA.
  • the target pre-mRNA is chosen as a target due to its expression within a specific cell type thus providing a mechanism for limiting expression of a novel RNA to a selected cell type.
  • the resulting chimeric RNA may provide a desired function, or may produce a gene product in the specific cell type.
  • the specific cells may include, but are not limited to those infected with viral or other infectious agents, benign or malignant neoplasms, or components of the immune system which are involved in autoimmune disease or tissue rejection.
  • the gene products encoded by the chimeric RNA can be any gene, including genes having clinical applications, for example, therapeutic genes, marker genes and genes encoding toxins.
  • the present invention provides compositions for use in generating novel chimeric nucleic acid molecules through targeted trans-splicing.
  • the synthetic PTMs of the invention comprise (i) one or more target binding domains that targets binding of the synthetic PTM to a pre-mRNA (ii) a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor site and/or 5' splice donor site; and (iii) one or more spacer regions to separate the RNA splice site from the target binding domain.
  • the synthetic PTMs can be engineered to contain any nucleotide sequence encoding a translatable peptide or protein product, hi yet another embodiment of the invention, the PTMs can be synthesized to contain nucleotide sequences that inhibit the translation of the chimeric RNA molecule.
  • the nucleotide sequences may contain translational stop codons or nucleotide sequences that form secondary structures and thereby inhibit translation.
  • the chimeric RNA may function as an antisense molecule thereby inhibiting splicing, nuclear transport or translation of the RNA to which it binds.
  • PTM molecules may be synthesized for use in the production of novel chimeric RNAs which may perform a function, such as inhibiting the translation of the RNA, or that encodes a protein that complements a defective or inactive protein in a cell or encodes a toxin which kills specific cells.
  • PTMs include PTMs designed to correct defects in the cystic fibrosis gene or the clotting factor NIII gene, or those designed to inhibit viral gene products such as papilloma virus gene products.
  • the design, construction and genetic engineering of such PTMs and demonstration of their ability to mediate successful trans-splicing reactions within the cell are described in detail in U.S. Patent ⁇ os. 6,083,702, 6,013,487 and 6,280,978 as well as patent Serial No.09/941,492, each of which is incorporated by reference in their entirety herein.
  • the target binding domain of the synthetic PTM endow the synthetic PTM with a binding affinity.
  • a target binding domain is defined as any molecule, i.e., nucleotide, protein, chemical compound, etc., that confers specificity of binding and anchors the pre-mRNA closely in space to the synthetic PTM so that the spliceosome processing machinery of the nucleus can trans-splice a portion of the synthetic PTM to a portion of the pre-mRNA.
  • the target binding domain of the synthetic PTM may contain multiple binding domains which are complementary to and in anti-sense orientation to the targeted region of the selected pre-mRNA.
  • the target binding domains may comprise up to several thousand nucleotides.
  • the binding domains may comprise at least 10 to 30 and up to several hundred or more nucleotides.
  • the specificity of the synthetic PTM can be increased significantly by increasing the length of the target binding domain.
  • the target binding domain may comprise several hundred nucleotides or more.
  • the target binding 'domain may be "linear" it is understood that the RNA may fold to form secondary structures that may stabilize the complex thereby increasing the efficiency of splicing.
  • a second target binding region may be placed at the 3' end of the molecule and can be incorporated into the PTM of the invention. Absolute complementarily, although preferred, is not required.
  • a sequence "complementary" to a portion of an RNA means a sequence having sufficient complementarity to be able to hybridize with the target pre-RNA, forming a stable duplex.
  • the ability to hybridize will depend on both the degree of complementarity and the length of the nucleic acid (See, for example, Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York). Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex.
  • a library of synthetic PTMs is genetically engineered to contain random nucleotide sequences in the target binding domain.
  • the synthetic PTMs may be genetically engineered so as to lack target binding domains. The goal of generating such a library of synthetic PTM molecules is that the library will contain a population of synthetic PTM molecules capable of binding to each RNA molecule expressed in the cell.
  • a recombinant , expression vector can be genetically engineered to contain a coding region for a PTM including a restriction endonuclease site that can be used for insertion of random . DNA fragments into the PTM to form random target binding domains.
  • the random nucleotide sequences to be included in the PTM as target binding domains can be generated using a variety of different methods well known to those of skill in the art, including but not limited to, partial digestion of DNA with restriction enzymes or mechanical shearing of DNA to generate random fragments of DNA. Random binding domain regions may also be generated by degenerate oligonucleotide synthesis.
  • the degenerate oligonucleotides can be engineered to have restriction endonuclease recognition sites on each end to facilitate cloning into a PTM molecule for production of a library of PTM molecules having degenerate binding domains.
  • Binding may also be achieved through other mechanisms, for example, through triple helix formation, aptamer interactions, antibody interactions or protein/nucleic acid interactions such as those in which the PTM is engineered to recognize a specific RNA binding protein, i.e., a protein bound to a specific target pre-mRNA.
  • the PTMs of the invention may be designed to recognize secondary structures, such as for example, hairpin structures resulting from intramolecular base pairing between nucleotides within an RNA molecule.
  • the PTM molecule also contains a 3' splice region that includes a branch point, pyrimidine tract and a 3' splice acceptor AG site and/or a 5' splice donor site.
  • Consensus sequences for the 5' splice donor site and the 3' splice region used in RNA splicing are well known in the art (See, Moore, et al., 1993, The RNA World, Cold Spring Harbor Laboratory Press, p. 303-358).
  • modified consensus sequences that maintain the ability to function as 5' donor splice sites and 3' splice regions may be used in the practice of the invention.
  • the 3' splice site consists of three separate sequence elements: the branch point or branch site, a polypyrimidine tract and the 3' splice site acceptor consensus sequence (YAG).
  • the branch point consensus sequence in mammals is YNYURAC
  • the underlined A is the site of branch formation.
  • a polypyrimidine tract is located between the branch point and the splice site acceptor and is important for efficient branch point utilization and 3' splice site recognition.
  • PTMs comprising a 3' acceptor site (AG) may be genetically engineered. Such PTMs may further comprise a pyrimidine tract and/or branch point sequence. Recently, pre-messenger RNA introns beginning with the dinucleotide
  • U12 introns As well as any sequences that function as splice acceptor/donor sequences may also be used in PTMs.
  • a spacer region to separate the RNA splice site from the target binding domain may also included in the PTM.
  • the spacer region can have features such as stop codons which would block any translation of an unspliced PTM and/or sequences that enhance trans-splicing to the target pre-mRNA.
  • a "safety" is also incorporated into the spacer, binding domain, or elsewhere in the PTM to prevent non-specific trans-splicing. This is a region of the PTM that covers elements of the 3' and/or 5' splice site of the PTM by relatively weak complementarity, preventing nonspecific trans-splicing.
  • the PTM is designed in such a way that upon hybridization of the binding /targeting portion(s) of the PTM, the 3' and/or 5' splice site is uncovered and becomes fully active.
  • the "safety” consists of one or more complementary stretches of cis- sequence (or could be a second, separate, strand of nucleic acid) which weakly binds to one or both sides of the PTM branch point, pyrimidine tract, 3' splice site and/or 5' splice site (splicing elements), or could bind to parts of the splicing elements themselves. This "safety” binding prevents the splicing elements from being active (i.e.
  • the binding of the "safety” may be disrupted by the binding of the target binding region of the PTM to the target pre-mRNA, thus exposing and activating the PTM splicing elements (making them available to trans-splice into the target pre-mRNA).
  • a nucleotide sequence encoding a translatable protein capable of producing an effect, such as cell death, or alternatively, one that restores a missing function or acts as a marker, is included in the PTM of the invention.
  • the nucleotide sequence can include those sequences encoding gene products missing or altered in known genetic diseases.
  • the nucleotide sequences can encode marker proteins or peptides which may be used to identify or image cells.
  • affinity tags such as, HIS tags (6 consecutive histidine residues) (Janknecht, et al., 1991, Proc. Natl. Acad. Sci.
  • PTMs containing such nucleotide sequences results in the production of a chimeric RNA encoding a fusion protein containing peptide sequences normally expressed in a cell linked to the peptide affinity tag.
  • the affinity tag provides a method for the rapid purification and identification of peptide sequences expressed in the cell.
  • the nucleotide sequences may encode toxins or other proteins which provide some function which enhances the susceptibility of the cells to subsequent treatments, such as radiation or chemotherapy.
  • a PTM molecule is fused to the Diphtheria toxin subunit A (Greenfield, L., et al., 1983, Proc. Nat'l. Acad. Sci. USA 80:6853-6857).
  • Diphtheria toxin subunit A contains enzymatic toxin activity and will function if delivered into human cells resulting in cell death.
  • various other known peptide toxins may be used in the present invention, including but not limited to, ricin, Pseudomonus toxin, Shiga toxin and exotoxin A.
  • Additional features can be added to the PTM molecule such as polyadenylation signals, or enhancer sequences to enhance splicing, additional binding regions, "safety"-self complementary regions, additional splice sites, or protective groups to modulate the stability of the molecule and prevent degradation.
  • sequences referred to as exonic splicing enhancers may also be included in the structure of the synthetic PTMs.
  • Transacting splicing factors namely the serine/arginine-rich (SR) proteins, have been shown to interact with such exonic splicing enhancers and modulate splicing (See, Tacke et al., 1999, Curr. Opin. Cell Biol.
  • Nuclear localization signals may also be included in the PTM molecule (Dingwell and Laskey, 1986, Ann .Rev. Cell Biol. 2:367-390; Dingwell and Laskey, 1991, Trends in Biochem. Sci. 16:478-481). Such nuclear localization signals can be used to enhance the transport of synthetic PTMs into the nucleus where trans-splicing occurs, hi addition, signals that enhance the retention of PTMs in the nucleus of the cell may be included in the PTM molecule.
  • PTMs of the invention include stop codons or other elements in the region between the binding domain and the splice site to prevent unspliced pre-mRNA expression, hi another embodiment of the invention, PTMs can be generated with a second anti-sense binding domain to promote binding to the 3' target intron or exon and to block the fixed authentic cis-5' splice site (U5 and/or Ul binding sites).
  • PTMs may also be generated that require a double-trans-splicing reaction for generation of a chimeric trans-spliced product. Such PTMs could be used to replace an internal exon which could be used for RNA repair. PTMs designed to promote two trans-splicing reactions are engineered as described above, however, they contain both 5' donor sites and 3' splice acceptor sites. In addition, the PTMs may comprise two or more binding domains and spacer regions. The spacer regions may be placed between the multiple binding domains and splice sites or alternatively between the multiple binding domains.
  • RNA molecules such as a 3' hairpin structure, circularization RNA, ribonucleotide base modification, or a synthetic analog can be incorporated into PTMs to promote or facilitate nuclear localization and spliceosomal incorporation, and intracellular stability.
  • PTMs when engineering PTMs for use in plant cells it may not be necessary to include conserved branch point sequences or polypyrimidine tracts as these sequences may not be essential for intron processing in plants.
  • a 3' splice acceptor site and/or 5' splice donor site such as those required for splicing in vertebrates and yeast, will be included.
  • the efficiency of splicing in plants may be increased by also including UA-rich intronic sequences. The skilled artisan will recognize that any sequences that are capable of mediating a trans-splicing reaction in plants may be used.
  • the PTMs of the invention can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization to the target mRNA, transport into the cell, etc.
  • modification of a PTM to reduce the overall charge can enhance the cellular uptake of the molecule.
  • modifications can be made to reduce susceptibility to nuclease or chemical degradation.
  • the nucleic acid molecules may be synthesized in such a way as to be conjugated to another molecule such as a peptides (e.g., for targeting host cell receptors in vivo), or an agent facilitating transport across the cell membrane (see, e.g., Letsinger et al, 1989, Proc. Natl. Acad. Sci.
  • nucleic acid molecules may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
  • nucleic acid molecules can be introduced as a means of increasing intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of ribonucleotides to the 5' and/or 3' ends of the molecule. In some circumstances where increased stability is desired, nucleic acids having modified internucleoside linkages such as 2'-0-methylation may be preferred. Nucleic acids containing modified internucleoside linkages may be synthesized using reagents and methods that are well known in the art (see, Uhlmann et al, 1990, Chem. Rev. 90:543-584; Schneider et al, 1990, Tetrahedron Lett. 31:335 and references cited therein).
  • the PTMs of the present invention are preferably modified in such a way as to increase their stability in the cells. Since RNA molecules are sensitive to cleavage by cellular ribonucleases, it may be preferable to use as the competitive inhibitor a chemically modified oligonucleotide (or combination of oligonucleotides) that mimics the action of the RNA binding sequence but is less sensitive to nuclease cleavage.
  • the synthetic PTMs can be produced as nuclease resistant circular molecules with enhanced stability (Puttaraju et al., 1995, Nucleic Acids Symposium Series No. 33:49-51; Puttaraju et al., 1993, Nucleic Acid Research
  • Y S (Stein, C. A., et al, 1988, Nucleic Acids Res., 16:3209-3221)
  • X S (Cosstick, R., et al, 1989, Tetrahedron Letters, 30, 4693-4696)
  • Y and Z S (Brill, W. K.-D., et al, 1989, J. Amer. Chem. Soc, 111 :2321-2322)
  • sugar modifications may be incorporated into the PTMs of the invention.
  • base modifications that may be made to the PTMs, including but not limited to use of: (i) pyrimidine derivatives substituted in the 5-position (e.g. methyl, bromo, fluoro etc) or replacing a carbonyl group by an amino group (Piccirilli, J. A., et al, 1990, Nature, 343:33-37); (ii) purine derivatives lacking specific nitrogen atoms (e.g. 7-deaza ademne, hypoxanthine) or functionahzed in the 8-position (e.g. 8-azido adenine, 8-bromo adenine) (for a review see Jones, A. S., 1979, Int. J. Biolog. Macromolecules, 1:194-207).
  • pyrimidine derivatives substituted in the 5-position e.g. methyl, bromo, fluoro etc
  • purine derivatives lacking specific nitrogen atoms (e.g. 7-deaza ademne,
  • the PTMs may be covalently linked to reactive functional groups, such as: (i) psoralens (Miller, P. S., et al, 1988, Nucleic Acids Res., Special Pub. No. 20, 113-114), phenanthrolines (Sun, J-S., et al, 1988, Biochemistry, 27:6039-6045), mustards (Nlassov, N.
  • reactive functional groups such as: (i) psoralens (Miller, P. S., et al, 1988, Nucleic Acids Res., Special Pub. No. 20, 113-114), phenanthrolines (Sun, J-S., et al, 1988, Biochemistry, 27:6039-6045), mustards (Nlassov, N.
  • oligonucleotide mimetics in which the sugar and internucleoside linkage, i.e., the backbone of the nucleotide units, are replaced with novel groups can be used.
  • a peptide nucleic acid P ⁇ A
  • P ⁇ A may be incorporated into synthetic PTMs to increase their stability and/or binding affinity for the target pre- mR ⁇ A.
  • synthetic PTMs may covalently linked to lipophilic groups or other reagents capable of improving uptake by cells.
  • the PTM molecules may be covalently linked to: (i) cholesterol (Letsinger, R. L., et al, 1989, Proc. Natl. Acad. Sci. USA, 86:6553-6556); (ii) polyamines (Lemaifre, M., et al, 1987, Proc. Natl. Acad. Sci, USA, 84:648-652); other soluble polymers (e.g. polyethylene glycol) to improve the efficiently with which the PTMs are delivered to a cell.
  • combinations of the above identified modifications may be utilized to increase the stability and delivery of PTMs into the target cell.
  • the PTMs of the invention can be used in methods designed to produce a novel chimeric RNA in a target cell.
  • the methods of the present invention comprise delivering to the target cell a PTM RNA molecule, wherein said PTM binds to a pre-mRNA and mediates a trans-splicing reaction resulting in formation of a chimeric RNA comprising a portion of the PTM molecule spliced to a portion of the pre-mRNA.
  • the synthetic PTMs of the invention are typically nucleic acid molecules or derivatives or modified versions thereof, single-stranded or double- stranded.
  • the synthetic PTMs of the invention are preferably RNA molecules composed of ribonucleosides with phosphodiester linkages or modified linkages.
  • nucleic acid also specifically includes nucleic acids composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil).
  • the synthetic PTMs of the invention may comprise, DNA/RNA, RNA protein or DNA/RNA/protein chimeric molecules that are designed to enhance the stability of the PTMs.
  • the synthetic PTMs of the invention can be prepared by any method known in the art for the synthesis of nucleic acid molecules.
  • the nucleic acids may be chemically synthesized using commercially available reagents and synthesizers by methods that are well known in the art (see, e.g., Gait, 1985, Oligonucleotide Synthesis: A Practical Approach, TRL Press, Oxford, England).
  • synthetic PTMs can be generated by in vitro transcription of DNA sequences encoding the PTM of interest.
  • DNA sequences can be incorporated into a wide variety of vectors downstream from suitable RNA polymerase promoters such as the T7, SP6, or T3 polymerase promoters.
  • Consensus RNA polymerase promoter sequences include the following: T7: TAATACGACTCACTATAGGGAGA
  • SP6 ATTTAGGTGACACTATAGAAGNG T3: AATTAACCCTCACTAAAGGGAGA.
  • the base in bold is the first base incorporated into RNA during transcription.
  • the underline indicates the minimum sequence required for efficient transcription.
  • RNAs may be produced in high yield via in vitro transcription using plasmids such as SPS65 and Bluescript (Promega Corporation, Madison, WT).
  • RNA amplification methods such as Q- ⁇ amplification can be utilized to produce the PTM of interest.
  • the PTMs can be generated by in vivo transcription within a cell.
  • the DNA encoding the PTM of interest may be recombinantly engineered into a variety of host vector systems that also provide for replication of the DNA in large scale and contain the necessary elements for directing high level transcription of the PTM.
  • a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of the PTM molecule.
  • Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce large quantities of the desired RNA.
  • Such vectors can be constructed by recombinant DNA technology methods standard in the art.
  • Vectors encoding the PTM of interest can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the PTM can be regulated by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Benoist, C. and Chambon, P.
  • Rous sarcoma virus Yamamoto et al, 1980, Cell 22:787-797
  • the herpes thymidine kinase promoter (Wagner et al, 1981, Proc. Natl. Acad. Sci. USA 78:1441-1445)
  • the regulatory sequences of the metallothionein gene (Brinster et al, 1982, Nature 296:39-42)
  • the viral CMV promoter the human chorionic gonadotropin- ⁇ promoter (Hollenberg et al., 1994, Mol Cell. Endocrinology 106:111-119), etc.
  • any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site.
  • viral vectors can be used which selectively infect the desired target cell.
  • the vectors encoding the PTM of interest may be designed to encode a PTM having a nucleotide tag that may be used to efficiently purify the PTM from the cell using affinity chromatography.
  • a selectable mammalian expression vector system can also be utilized.
  • a number of selection systems can be used, including but not limited to selection for expression of the herpes simplex virus thymidine kinase, hypoxanthine-guanine phosphoribosyltransterase and adenine phosphoribosyl tranferase protein in tk-, hgprt- or aprt- deficient cells, respectively.
  • anti-metabolic resistance can be used as the basis of selection for dihydrofolate tranferase (dhfr), which confers resistance to methotrexate; xanthine-guanine phosphoribosyl transferase (gpt), which confers resistance to mycophenolic acid; neomycin (neo), which confers resistance to amino glycoside G-418; and hygromycin B phosphotransferase (hygro) which confers resistance to hygromycin.
  • the cell culture is transformed at a low ratio of vector to cell such that there will be only a single vector, or a limited number of vectors, present in any one cell.
  • Vectors for use in the practice of the invention include any eukaryotic expression vectors, including but not limited to viral expression vectors such as those derived from the class of retro viruses or adeno-associated viruses.
  • the PTMs may be purified by any suitable means, as are well known in the art.
  • the PTMs can be purified by gel filtration, affinity or antibody interactions, reverse phase chromatography or gel electrophoresis.
  • the method of purification will depend in part on the size, charge and shape of the nucleic acid to be purified.
  • the PTM's of the invention can be synthesized in the presence of modified or substituted nucleotides to increase stability, uptake or binding of the PTM to a target pre-mRNA.
  • the PTMs may be modified with peptides, chemical agents, antibodies, or nucleic acid molecules, for example, to enhance the physical properties of the PTM molecules. Such modifications are well known to those of skill in the art.
  • compositions and methods of the present invention will have a variety of different applications including gene regulation, gene repair, targeted cell death and real time imaging.
  • trans-splicing can be used to introduce a protein with toxic properties into a cell.
  • synthetic PTMs can be engineered to bind to viral mRNA and destroy the function of the viral mRNA, or alternatively, to destroy any cell expressing the viral mRNA.
  • synthetic PTMs can be engineered to place a stop codon in a deleterious mRNA transcript thereby decreasing the expression of that transcript.
  • Targeted trans-splicing including double-trans-splicing reactions, 3' exon replacement and/or 5' exon replacement can be used to repair or correct transcripts that are either truncated or contain mutations.
  • the synthetic PTMs of the invention are designed to trans-splice a targeted transcript upstream or downstream of a specific mutation or upstream of a premature 3' termination and correct the mutant transcript via a trans-splicing reaction which replaces the portion of the transcript containing the mutation with a functional or therapeutic sequence.
  • double trans-splicing reactions may be used for the selective expression of a toxin in tumor cells.
  • synthetic PTMs can be designed to replace the second exon of the human ⁇ -chronic gonadotropin-6 ( ⁇ hCG6) gene transcripts and to deliver an exon encoding the subunit A of diptheria toxin (DT- A). Expression of DT-A in the absence of subunit B should lead to toxicity only in the cells expressing the gene.
  • ⁇ hCG6 is a prototypical target for genetic modification by trans-splicing. The sequence and the structure of the ⁇ hCG6 gene are completely known and the pattern of splicing has been determined.
  • the ⁇ hCG6 gene is highly expressed in many types of solid tumors, including many non-germ line tumors, but the ⁇ hCG6 gene is silent in the majority cells in a normal adult. Therefore, the ⁇ hCG6 pre-mRNA represents a desirable target for a trans-splicing reaction designed to produce tumor-specific toxicity.
  • the first exon of ⁇ hCG6 pre-mRNA is ideal in that it encodes only five amino acids, including the initiator AUG, which should result in minimal interference with the proper folding of the DT-A toxin while providing the required signals for effective translation of the trans-spliced mRNA.
  • the DT-A exon which is designed to include a stop codon to prevent chimeric protein formation, will be engineered to trans-splice into the last exon of the ⁇ hCG6 gene.
  • the last exon of the ⁇ hCG6 gene provides the construct with the appropriate signals to polyadenylate the mRNA and ensure translation.
  • Cystic fibrosis (CF) is one of the most common fatal genetic disease in humans.
  • cystic fibrosis transmembrane conductance regulator CFTR
  • a trans-splicing reaction will be used to correct a genetic defect in the DNA sequence encoding the cystic fibrosis transmembrane regulator (CFTR) whereby the DNA sequence encoding the cystic fibrosis trans-membrane regulator protein is expressed and a functional chloride ion channel is produced in the airway epithelial cells of a patient.
  • CTR cystic fibrosis transmembrane regulator
  • cystic fibrosis mutation is a deletion of the three nucleotides in exon 10 that encode phenylalanine at position 508 of the CFTR amino acid sequence.
  • a trans-splicing reaction was capable of correcting the deletion at position 508 in the CFTR amino acid sequence.
  • the PTM used for correction of the genetic defect contained a CFTR binding domain complementary to intron 9 sequence, a spacer sequence, a branch point, a polypyrimidine tract, a 3' splice site and a wild type CFTR BD exon 10 sequence.
  • the successful correction of the mutated DNA encoding CFTR utilizing a trans-splicing reaction supports the general application of PTMs for correction of genetic defects.
  • trans-splicing may be used to place the expression of any engineered gene under the natural regulation of a chosen target plant gene, thereby regulating the expression of the engineered gene.
  • Trans-splicing may also be used to prevent the expression of engineered genes in non-host plants or to convert an endogenous gene product into a more desirable product.
  • compositions of the invention into cells, including conjugating PTMs with cationic lipids (Lu,D., et al, 1994, Cancer Gene Ther., 1 :245-252) or polycations, DEAE- dextran (Malone, R.W., et al, 1989, Proc. Natl Acad. Sci. USA, 86:6077-6081), ⁇ oly(L-lysine) (Fisher,K.J. and Wilson, J.M., 1997, Biochem. J., 321:49-58) or dendrimers (Sfrobel, I., et al, 2000, Gene Ther., 7:2028-2035).
  • a composition may be prepared in which the synthetic PTMs are associated with, or impregnated within, a matrix, to form a "matrix-PTM composition" and the matrix-PTM composition is then placed in contact with the cells or tissue expressing the target mRNA.
  • the matrix may become impregnated with the synthetic PTM simply by soaking the matrix in a solution containing the synthetic PTM for a brief period of time of anywhere from about 5 minutes or so, up to and including about an hour.
  • Matrix-PTM compositions are all those in which a synthetic PTM is adsorbed, absorbed, or otherwise maintained in contact with the matrix.
  • the type of matrix that may be used in the compositions and methods of the invention is virtually limitless, so long as it is a "biocompatible matrix.” This means that the matrix has all the features commonly associated with being “biocompatible,” in that it is in a form that does not produce an adverse, allergic or other untoward reaction when administered to an animal, and it is also suitable for placing in contact with cells or tissue.
  • Direct in vivo synthetic PTM transfer may be achieved with formulations of synthetic PTMs trapped in liposomes (Ledley et al, 1987); or in proteoliposomes that contain viral envelope receptor proteins (Nicolau et al, 1983)
  • the present invention relates to the synthesis of novel cationic, amphiphilic lipids and their application as synthetic PTM transfer vehicles in vitro and in vivo.
  • a variety of different lipids diglycerides, steroids
  • variable cationic molecules amino acids, biogenic amines).
  • the cationic lipids employed for the generation of liposomes should be non-toxic, fully biodegradable and should not cause an immunoreaction.
  • the liposomes should form complexes with the synthetic PTMs with high efficacy, protect the synthetic PTM against degradation, and provide high transfection efficiencies.
  • liposomes can be engineered in a receptor specific manner. Methods for synthesis of cationic lipids are well known to those of skill in the art.
  • Receptor-mediated gene transfer may also be used to introduce synthetic PTMs into target cells, both in vitro and in vivo.
  • Such transfer involves linking the synthetic PTM to a polycationic protein (usually poly-L-lysine) containing a covalently attached ligand, which is selected to target a specific receptor on the surface of the cell of interest.
  • the nucleic acid is taken up by the cell and expressed.
  • Cell-specific delivery of a synthetic PTM using a conjugate of a polynucleic acid binding agent such as polylysine, polyarginine, polyornithine, histone, avidin, or protamine
  • a tissue receptor-specific protein ligand may also be achieved using the method of Wu et al. (U.S. Patent No. 5,166,320).
  • the "naked" synthetic PTM may be directly injected into the host (Dubenski et al, Proc. Natl. Acad. Sci. USA,
  • the synthetic PTM may be precipitated using calcium phosphate and inj ected together with a suitable carrier.
  • compositions and methods can be used to treat cancer and other serious viral infections, autoimmune disorders, and other pathological conditions in which the alteration or elimination of a specific cell type would be beneficial.
  • compositions and methods may also be used to provide a gene encoding a functional biologically active molecule to cells of an individual with an inherited genetic disorder where expression of the missing or mutant gene product produces a normal phenotype.
  • the present invention also provides for pharmaceutical compositions comprising an effective amount of a synthetic PTM and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the synthetic is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical sciences" by E.W. Martin.
  • compositions are administered: (1) in diseases or disorders involving an absence or decreased (relative to normal or desired) level of an endogenous protein or function, for example, in hosts where the protein is lacking, genetically defective, biologically inactive or underactive, or under expressed; or (2) in diseases or disorders wherein, in vitro or in vivo, assays indicate the utility of synthetic PTMs that inhibit the function of a particular protein.
  • the activity of the protein encoded for by the chimeric mRNA resulting from the synthetic PTM mediated trans-splicing reaction can be readily detected, e.g., by obtaining a host tissue sample (e.g., from biopsy tissue) and assaying it in vitro for mRNA or protein levels, structure and/or activity of the expressed chimeric mRNA.
  • a host tissue sample e.g., from biopsy tissue
  • chimeric mRNA e.g., Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc.
  • hybridization assays to detect formation of chimeric mRNA expression by detecting and/or visualizing the presence of chimeric mRNA (e.g. , Northern assays, dot blots, in situ hybridization, and Reverse- Transcription PCR, etc.), etc.
  • direct visualization of a reporter gene either encoded by the synthetic PTM or associated with a PTM may be carried out.
  • the present invention also provides for pharmaceutical compositions comprising an effective amount of a synthetic PTM or a nucleic acid encoding a synthetic PTM, and a pharmaceutically acceptable carrier, hi a specific embodiment, the term “phamiaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical sciences" by E.W. Martin.
  • compositions of the invention may be desirable to administer locally to the area in need of treatment.
  • This may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
  • Other control release drug delivery systems such as nanoparticles, matrices such as controlled-release polymers, hydrogels.
  • the synthetic PTM will be administered in amounts which are effective to produce the desired effect in the targeted cell. Effective dosages of the synthetic PTMs can be determined through procedures well known to those in the art which address such parameters as biological half-life, bioavailability and toxicity. The amount of the composition of the invention which will be effective will depend on the nature of the disease or disorder being treated, and can be determined by standard clinical techniques, hi addition, in vitro assays may optionally be employed to help identify optimal dosage ranges.
  • the present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • EXAMPLE PRODUCTION OF Ti NS-SPLICING MOLECULES The following example demonstrates successful transfer of PTMs into cells and accurate replacement of an internal exon by a double-trans-splicing between a target pre-mRNA and a PTM RNA containing both 3' and 5' splice sites leading to production of full length functionally active protein.
  • Plasmids, pc3.1DSPTM7 and pc3.1DSPTM19 (containing T7 promoter) are described in patent application Serial No. 09/941,492.
  • the plasmids were digested with Stu I restriction enzyme at 37°C for completion (2-3 hr).
  • the products were extracted once with buffered phenol and once with chloroform or purified using Qiaquick PCR purification kit (Qiagen).
  • the DNA was recovered by ethanol precipitation and was washed twice with 70% ethanol, air dried for 5 min, re-suspended with sterile water and used for in vitro transcription.
  • the reactions were incubated at 37° C for 2-3 hr and the DNA template was destroyed by adding 1 ⁇ l of DNasel (2U/ml) and continuing the incubation at 37° C for an additional 15 min. The reactions were terminated by adding formamide gel loading buffer followed by heating for 3 min at 95° C.
  • RNA In vitro transcribed RNA was purified on a 5-6% denaturing polyacrylamide gel. RNA bands were visualized by UV shadowing. The RNA was eluted from the gel into 0.1% SDS, 10 mM EDTA and recovered by ethanol precipitation, washed twice with 70% ethanol, air dried, re-suspended in sterile water and used for transfections .
  • RNA preparation was removed by treating with DNasel at 37°C for 30-45 min.
  • Total cell RNA (2.5 ⁇ g) from the transfections was converted to cDNA using the MMLV reverse transcriptase enzyme (Promega) in a 25 ⁇ l reaction following the manufacturers protocol with the addition of 50 units RNase Inhibitor (Life Technologies) and 200 ng Lac-6R gene specific primer: (5 ' -CTAGGCGGCCGCCTGCTGGTGTTTTGCTTCC).
  • cDNA synthesis reactions were incubated at 42°C for 60 min followed by incubation at 95°C for 5 min. This cDNA template was used for PCR reactions. PCR amplifications were performed using 100 ng primers and 1 ⁇ l template (RT reaction) per 50 ⁇ l PCR reaction.
  • a typical reaction contained -25 ng of cDNA template, 100 ng of primers (common to cis- and trans-spliced products) (KI-1F, 5'- GTTTCGCTAAATACTGGCAGG and, Lac-6R, 5'-
  • IX REDTaq PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KC1, 1.1 mM MgCl 2 and 0.1% gelatin), 200 ⁇ M dNTPs and 1.5 units of REDTaq DNA polymerase (Sigma, Saint Louis, Missouri). PCR reactions were performed with an initial pre-heating at 94°C for 2 min 30 sec followed by 20 cycles of 94°C for 30 sec (denaturation), 60°C for 36 sec (annealing) and 72°C for 1 min (extension) followed by a final extension at 72°C for 7 min.
  • PCR products were then digested with Sph I and Dde I restriction endonucleases, which specifically cleaves cis-spliced product.
  • Trans-spliced product was isolated using Lac-21 (has biotin at the 5' end) as a hybridization probe.
  • the purified trans- spliced product was subjected to a 2nd round of nested PCR using primers KI-2F (5'- CTGGCAGGCGTTTCGTCAG) and Lac-6R. Authenticity of the trans-spliced product was further confinned by diagnostic digestion with Pvu I restriction enzyme which specifically cleaves the trans-spliced product. 6.1.4. ⁇ -GALACTOSIDASE ASSAY
  • Total cellular protein was isolated by freeze thaw method and assayed for ⁇ -galactosidase activity using a ⁇ -gal assay kit (Invitrogen, Carlsbad, CA). Protein concentration was measured by the dye-binding assay using Bio-Rad protein assay reagents (BIO-RAD, Hercules, CA).
  • RNAs were exogenously synthesized using bacteriphage T7 RNA polymerase in vitro, gel purified and used for transfections.
  • both DSPTM6 and DSPTM7 produced the expected trans-spliced 220 bp RT-PCR product in 293T cells (upper panel).
  • the authenticity of this product was confirmed by diagnostic digestion using Sph I, which cuts the cis-spliced product specifically (lower panel, lanes 1 and 2) and Pvu I that cuts the trans-spliced product specifically (lower panel, lanes 4 and 5).
  • RT-PCR amplified.product was excised, re-amplified using KI-2F and Lac6R primers and sequenced directly using KI-2F or Lac-6R primers. As shown in Figure 6C, trans- splicing occurred exactly at the predicted splice sites, confirming the precise internal exon substitution by the double trans-splicing events.
  • Trans-splicing efficiency and specificity of DSPTM18, DSPTM19 and DSPTM7 were tested in stable cells that express double splicing HCG target pre- mRNA endogenously.
  • RT-PCR analyses of the total RNA that were transfected with DSPTM18 and DSPTM19 produced the expected 220 bp trans-spliced product (Fig. 6B, lanes 3 and 4).
  • No trans-spliced product was detected in cells that were mock transfected or transfected with DSPTM7 that is targeted to CFTR target pre-mRNA (lanes 1 and 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des méthodes et des compositions servant à apporter des molécules synthétiques de pré-trans-épissage (MPT synthétiques) dans une cellule cible. Les compositions selon l'invention comprennent des molécules synthétiques de pré-trans-épissage présentant une stabilité améliorée contre la dégradation chimique et enzymatique. Les MPT synthétiques sont prévues pour interagir avec une molécule d'ARN messager de précurseur cible naturel (pré-ARNm cible) et induire une réaction de trans-épissage ayant pour résultat de produire une nouvelle molécule d'ARN chimère (ARN chimère).
PCT/US2003/004622 2002-02-12 2003-02-12 Methodes et compositions destinees a etre utilisees dans le trans-epissage d'arn induit par une epissosome WO2003069311A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003568382A JP2006505242A (ja) 2002-02-12 2003-02-12 スプライセオソームにより媒介されるｒｎａトランス−スプライシングにおいて使用するための方法および組成物
CA002475802A CA2475802A1 (fr) 2002-02-12 2003-02-12 Methodes et compositions destinees a etre utilisees dans le trans-epissage d'arn induit par une epissosome
EP03711065A EP1539788A2 (fr) 2002-02-12 2003-02-12 Methodes et compositions destinees a etre utilisees dans le i trans /i -epissage d'arn induit par une epissosome
AU2003215249A AU2003215249B2 (en) 2002-02-12 2003-02-12 Methods and compositions for use in spliceosome mediated RNA trans-splicing

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/076,248 2002-02-12
US10/075,028 US20030153054A1 (en) 2002-02-12 2002-02-12 Methods and compositions for use in spliceosome mediated RNA trans-splicing
US10/075,028 2002-02-12
US10/076,248 US20020193580A1 (en) 1995-12-15 2002-02-12 Methods and compositions for use in spliceosome mediated RNA trans-splicing

Publications (2)

Publication Number Publication Date
WO2003069311A2 true WO2003069311A2 (fr) 2003-08-21
WO2003069311A3 WO2003069311A3 (fr) 2005-04-21

Family

ID=27736827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004622 WO2003069311A2 (fr) 2002-02-12 2003-02-12 Methodes et compositions destinees a etre utilisees dans le trans-epissage d'arn induit par une epissosome

Country Status (5)

Country Link
EP (1) EP1539788A2 (fr)
JP (1) JP2006505242A (fr)
AU (1) AU2003215249B2 (fr)
CA (1) CA2475802A1 (fr)
WO (1) WO2003069311A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518423A (ja) * 2004-01-23 2007-07-12 イントロン、インコーポレイテッド スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
EP2151248A1 (fr) 2008-07-30 2010-02-10 Johann Bauer Molécules trans-splicing pre-mARN améliorées et leurs utilisations
US10987433B2 (en) 2015-11-19 2021-04-27 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
US11993776B2 (en) 2018-04-17 2024-05-28 Ascidian Therapeutics, Inc. Trans-splicing molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013487A (en) * 1995-12-15 2000-01-11 Mitchell; Lloyd G. Chimeric RNA molecules generated by trans-splicing
US6083702A (en) * 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013487A (en) * 1995-12-15 2000-01-11 Mitchell; Lloyd G. Chimeric RNA molecules generated by trans-splicing
US6083702A (en) * 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518423A (ja) * 2004-01-23 2007-07-12 イントロン、インコーポレイテッド スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
EP2151248A1 (fr) 2008-07-30 2010-02-10 Johann Bauer Molécules trans-splicing pre-mARN améliorées et leurs utilisations
US10987433B2 (en) 2015-11-19 2021-04-27 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
US11993776B2 (en) 2018-04-17 2024-05-28 Ascidian Therapeutics, Inc. Trans-splicing molecules

Also Published As

Publication number Publication date
AU2003215249A1 (en) 2003-09-04
EP1539788A2 (fr) 2005-06-15
JP2006505242A (ja) 2006-02-16
AU2003215249B2 (en) 2008-07-03
WO2003069311A3 (fr) 2005-04-21
CA2475802A1 (fr) 2003-08-21

Similar Documents

Publication Publication Date Title
AU773186B2 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6083702A (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US8053232B2 (en) Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
JP5053850B2 (ja) 抗体遺伝子導入および抗体ポリペプチド産生のためのｒｎａトランススプライシングの使用
JP2007518423A (ja) スプライセオソーム仲介型ｒｎａトランススプライシングを使用するアポａ−１及びその変異体の発現
US20060134658A1 (en) Use of RNA trans-splicing for generation of interfering RNA molecules
AU2003215249B2 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
EP1521766B1 (fr) Trans-epissage d'arn a mediation par spliceosome (technique smart) et correction de defauts genetiques de facteur viii a l'aide du trans-epissage d'arn a mediation par spliceosome
US20020193580A1 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030153054A1 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030077754A1 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020115207A1 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20030148937A1 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20040214263A1 (en) Spliceosome mediated RNA trans-splicing
US20040126774A1 (en) Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
JP2009000120A (ja) スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物
US20060088938A1 (en) Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20040038396A1 (en) Spliceosome mediated RNA trans-splicing for correction of factor VIII genetic defects

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003215249

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003568382

Country of ref document: JP

Ref document number: 2475802

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003711065

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003711065

Country of ref document: EP